Delaware will be the 22nd state to launch adult-use cannabis sales when dispensaries open for business on Aug. 1, state regulators announced this week.

The Delaware Office of the Marijuana Commissioner (OMC) gave the green light on July 1 for the state’s 13 existing medical cannabis dispensaries, known as medical marijuana compassion centers, to transition to serving adult-use customers 21 years and older in a first-mover advantage beginning next month.

The forthcoming launch date comes more than two years—831 days to be exact—since former Delaware Gov. John Carney allowed the Delaware Marijuana Control Act to be enacted without his signature in April 2023.

Delaware Marijuana Commissioner Joshua Sanderlin, who was nominated in April 2025 to take the reins, is now overseeing the program rollout.

“The start of legal adult-use marijuana sales reflects the tireless efforts of our regulatory team and our strong partnerships with state agencies, industry stakeholders and community leaders,” Sanderlin said. “Our focus is on building a safe, equitable and accountable marijuana market that delivers real benefits to Delawareans. We will continue to issue conditional licenses to previously selected applicants to ensure they can begin operations once active.” 

The OMC finalized regulations for a commercial marketplace in September 2024 under former Marijuana Commissioner Rob Coupe, who had originally hoped for a March 2025 sales launch with a strong focus on social equity licensees.

The OMC held lotteries in October 2024 and December 2024 to award 125 adult-use licenses to cultivators, manufacturers, retailers and testing labs, including for 30 new dispensaries, half of which were reserved for social equity applicants.

However, the spring 2025 sales launch was delayed when the Federal Bureau of Investigation (FBI) rejected the OCM’s application in March for a service code needed to initiate Delaware’s statutorily required criminal background checks via a fingerprinting system for new licensees. Existing medical operators have already undergone the background checks.

Delaware Gov. Matt Meyer signed legislation less than a month later to align state law with FBI standards for the service code, putting the adult-use sales launch via an equitable rollout back on track. However, the OCM did not specify when new licensees could enter the market in a July 1 press release announcing the Aug. 1 sales commencement.

“Delaware has taken a major step forward by launching a legal adult-use cannabis market that prioritizes equity, safety and accountability,” Meyer said. “This new industry will generate critical revenue to strengthen our schools, infrastructure and public health systems, while creating real opportunities for entrepreneurs. This revenue also gives us a powerful tool to invest in the communities most impacted by the war on drugs, addressing past wrongs and ensuring that the benefits of this new market reach every corner of our state. I’m proud we’re moving quickly and thoughtfully to build a cannabis market that reflects our values and expands opportunity for every Delawarean.”

Initially, there was no path for existing medical cannabis operators to transition to the expanded marketplace under the 2023 legalization legislation. However, the General Assembly passed follow-up legislation in 2024 to provide that pathway to help kickstart the adult-use program. Without medical cannabis companies providing products via established cultivation operations, the sales launch could have remained sidelined for years as new licensees build out their grow facilities.

Still, conversion licenses for medical cannabis companies to transition to adult-use operations came at a significant cost: $200,000 for cultivators, and $100,000 for manufacturers and retailers. The conversion fees resulted in $4 million in funding to support Delaware’s social equity applicant start-up grants, according to the OMC.

MariMed CEO Jon Levine, whose company acquired First State Compassion Center’s cultivation and processing facilities and two dispensaries in March, said he’s excited to participate in the expansion of Delaware’s cannabis program with the sales launch next month.

“Our Delaware business unit, First State Compassion, was the first licensed operator in the state 10 years ago, and since then, we have proudly served the state’s medical cannabis patients,” Levine said. “We are looking forward to opening our doors to many more residents and the nearly 30 million tourists who visit the state annually.”

In anticipation of the sales launch, MariMed has already improved its Wilmington and Lewes dispensaries to help ensure that an increase in customer traffic does not impact the experience and product selections that its medical cannabis patients have enjoyed up until this point, Levine said. The company has also begun scaling production at its cultivation and processing facilities to meet the expected rise in demand.

Delaware’s adult-use marketplace could provide $215 million in economic activity, including more than $40 million in annual state tax revenue, Spotlight Delaware reported earlier this year.

Blackbird operators can now streamline operations and elevate brand presence with custom packaging solutions designed for speed, compliance, and impact.

RollPros is excited to launch our new packaging and design services, built specifically for pre roll brands that are ready to stand out.

From certified child-resistant packs and pre roll tubes to fully branded kits and compliant label design, our new packaging solutions are designed to help you move faster, look sharper, and stay compliant. These services meet the same standards of precision and consistency the industry already expects from the Blackbird, without the inflated costs often seen from traditional packaging vendors.

We’ve always wanted to be more than your equipment supplier. Many of our customers already source your crutches and papers from us, so adding packaging just made sense. One vendor, one point of contact, one smooth workflow. It is not only more convenient, it is more cost effective.

“This is a huge step forward in our goal to be a one-stop shop for pre roll manufacturers,” says Johnathan McFarlane, VP of Sales and Marketing at RollPros. “Having not only their equipment but also their consumables, packaging, and even design under one vendor is a huge value-add for our customers. It will make their ops more streamlined, efficient, and cost-effective. We’ve always wanted to be their easy button, and we’re finally there.”

Whether you’re launching your first product or scaling a multi-state operation, our packaging is built to meet the highest standards in design, function, and compliance. We use premium-grade materials that are made to fit Blackbird pre rolls perfectly, so you can avoid the one-size-fits-none packaging problems that slow brands down.

Need help with design? We’ve got that covered too. Our team can create a new visual identity from scratch or apply your existing brand look across your entire product line. Every touchpoint will reflect your brand and speak directly to your customers.

The result is packaging that does more than check compliance boxes. It grabs attention, reinforces brand identity, and builds trust with consumers from the very first impression.

We’re here to make things easier. Learn more and get started at https://rollpros.com/packaging/ or reach out to our sales team directly. Let’s make your brand stand out on every shelf. 

In another sign that marijuana reform may be taking a back seat amid competing political priorities during the second Trump administration, the Congressional Cannabis Caucus has yet to have a single meeting this legislative session, one of its members tells Marijuana Moment.

Asked about the status of the caucus, Rep. Ilhan Omar (D-MN), one of the four bipartisan co-chairs of the group, said it hasn’t convened at this point—even as several cannabis bills have been filed this Congress, including those originating from group members.

“The Cannabis Caucus still hasn’t met yet?” Marijuana Moment asked.

“Nope,” Omar said, while also stating that she’s yet to review provisions of an agriculture spending bill that would ban consumable hemp products containing any quantifiable amount of THC.

A spokesperson for the other Democratic co-chair of the caucus, Rep. Dina Titus (D-NV), did clarify that while the group itself hasn’t met, staffers for the bipartisan lawmakers have been in touch and they expect a formal meeting of the caucus “will happen” after a key budget bill that’s been occupying much of Congress’s time recently is “processed.”

Marijuana Moment also reached out to the offices of Omar and the two Republican caucus co-chairs—Reps. Dave Joyce (R-OH) and Brian Mast (R-FL)—for additional comment on the status of the group and future plans for meetings, but representatives did not respond by the time of publication.

While there are various competing priorities at the time, including key appropriations legislation, it’s struck some advocates as odd that the caucus hasn’t at least held an initial meeting—especially considering that marijuana and hemp issues have been raised this session, including the filing of reform bills such as one from Joyce to end federal prohibition and let states decide on the issue.

Omar and Titus are the newest co-chairs of the Cannabis Caucus, replacing former Reps. Earl Blumenauer (D-OR) and Barbara Lee (D-CA). In a sense, that makes it all the more notable that the coalition wouldn’t have had an introductory meeting on a bipartisan basis to align on priorities for the 119th Congress, which is now a quarter over.

That said, both Democratic leaders separately talked about the group’s legislative agenda for marijuana reform during a Last Prisoner Project (LPP) event in April.

Beyond filing a bill together—which would remove a restriction that’s prevented the White House drug czar from advocating for the legalization of marijuana or other Schedule I drugs under the Controlled Substances Act (CSA)—Omar and Titus previewed bipartisan legislation to end federal prohibition in legal states and free up the industry to access banking services.

To that end, Joyce recently reintroduced a bill titled the Strengthening the Tenth Amendment Through Entrusting States (STATES) 2.0 Act, which would end federal marijuana prohibition in states that have legalized it, while providing for a basic federal regulatory framework for cannabis products.

At the administrative level, there’s increased pressure for President Donald Trump to independently act on reform—including a call for rescheduling and banking access from top athletes and celebrities such as Mike Tyson who are imploring the president to go further than his predecessor, former President Joe Biden.

Meanwhile, Trump’s first pick for attorney general in the current administration, former Rep. Matt Gaetz (R-FL), recently reiterated his own support for rescheduling cannabis—suggesting in an interview with a Florida Republican lawmaker that the GOP could win more of the youth vote by embracing marijuana reform.

On marijuana rescheduling, the president did endorse the policy change on the campaign trail. But he’s been publicly silent on the issue since taking office. Gaetz said last month that Trump’s endorsement of a Schedule III reclassification was essentially an attempt to shore up support among young voters rather than a sincere reflection of his personal views about cannabis.

A survey conducted by a GOP pollster affiliated with Trump that was released in April found that a majority of Republicans back a variety of cannabis reforms, including rescheduling. And, notably, they’re even more supportive of allowing states to legalize marijuana without federal interference compared to the average voter.

—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—

Separately, Trump picked former Florida Attorney General Pam Bondi (R) to run DOJ, and the Senate confirmed that choice. During her confirmation hearings, Bondi declined to say how she planned to navigate key marijuana policy issues. And as state attorney general, she opposed efforts to legalize medical cannabis.

Adding to the uncertainty around the fate of the rescheduling proposal, Trump’s nominee to lead DEA, Terrance Cole, has previously voiced concerns about the dangers of marijuana and linked its use to higher suicide risk among youth.

During an in-person hearing before the Judiciary Committee in April, Cole said examining the rescheduling proposal will be “one of my first priorities” if he was confirmed for the role, saying it’s “time to move forward” on the stalled process—but again without clarifying what end result he would like to see.

DEA recently notified an agency judge that the proceedings are still on hold—with no future actions currently scheduled. The matter sat without action before an acting administrator, Derek Maltz, who has called cannabis a “gateway drug” and linked its use to psychosis. Maltz has since left the position.

Amid the stalled marijuana rescheduling process that’s carried over from the last presidential administration, congressional researchers recently reiterated that lawmakers could enact the reform themselves with “greater speed and flexibility” if they so choose, while potentially avoiding judicial challenges.

The LCB contributed reporting from Washington, D.C. 

Mike Tyson Tells Trump To Reschedule Marijuana And Free Prisoners In Fox News Appearance